BCM
DRNA

Burrage Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Burrage Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-104,047
Closed -$2.29M – 37
2019
Q4 		$2.29M Buy
+104,047
New +$2.09M 1.54% 21

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Burrage Capital Management's DRNA Position: Q1 2020 in Review

Burrage Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 104,047 shares — an estimated $2.29M sold.

Burrage Capital Management first reported a position in DRNA in Q4 2019 and held it in 1 quarter. The position peaked at $2.29M in Q4 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

  • Burrage Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Burrage Capital Management sold 104,047 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2.29M.
  • Burrage Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Burrage Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.29M in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Burrage Capital Management's 13F filing for Q1 2020, filed 14 May 2020.